ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 36 for:    small cell lung ca | Recruiting, Not yet recruiting, Available Studies

Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03382561
Recruitment Status : Recruiting
First Posted : December 26, 2017
Last Update Posted : May 23, 2018
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This randomized phase II clinical trial studies how well cisplatin, carboplatin, and etoposide work when given together with nivolumab in treating patients with extensive stage lung cancer. Drugs used in chemotherapy, such as cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving cisplatin, carboplatin, and etoposide together with nivolumab may work better in treating patients with extensive stage lung cancer.

Condition or disease Intervention/treatment Phase
Extensive Stage Small Cell Lung Carcinoma Drug: Carboplatin Drug: Cisplatin Drug: Etoposide Other: Laboratory Biomarker Analysis Biological: Nivolumab Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To evaluate the progression-free survival (PFS) of patients with extensive stage small cell lung cancer (ED-SCLC) treated with cisplatin/carboplatin and etoposide (CE) or CE with nivolumab (CEN) as front-line treatment.

SECONDARY OBJECTIVES:

I. To estimate overall survival of patients with ED-SCLC treated with cisplatin/carboplatin and etoposide (CE) or CE with nivolumab (CEN) as front-line treatment.

II. To assess best overall response rate after treatment with CE with or without nivolumab as first line treatment.

III. To evaluate the toxicity profile of nivolumab with CE.

TERTIARY OBJECTIVES:

I. To evaluate immune biomarkers and biomarkers correlatives. II. To evaluate serial circulating tumor deoxyribonucleic acid (DNA) and explore whether clinical outcome is associated with fluctuations in DNA levels following the administration of therapy.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1, carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients continue to receive nivolumab IV over 30 minutes every 2 weeks for up to 2 years.

ARM B: Patients receive carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for less than 2 years from registration, every 6 months if the patient is 2-3 years from registration, and yearly for up to 5 years.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Actual Study Start Date : May 2, 2018
Estimated Primary Completion Date : November 30, 2018
Estimated Study Completion Date : November 30, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Arm A (nivolumab, CE)
Patients receive nivolumab IV over 30 minutes on day 1, carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients continue to receive nivolumab IV over 30 minutes every 2 weeks for up to 2 years.
Drug: Carboplatin
Given IV
Other Names:
  • Blastocarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Carbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatinum
  • Paraplatin
  • Paraplatin AQ
  • Paraplatine
  • Platinwas
  • Ribocarbo
Drug: Cisplatin
Given IV
Other Names:
  • Abiplatin
  • Blastolem
  • Briplatin
  • CDDP
  • Cis-diammine-dichloroplatinum
  • Cis-diamminedichloridoplatinum
  • Cis-diamminedichloro Platinum (II)
  • Cis-diamminedichloroplatinum
  • Cis-dichloroammine Platinum (II)
  • Cis-platinous Diamine Dichloride
  • Cis-platinum
  • Cis-platinum II
  • Cis-platinum II Diamine Dichloride
  • Cismaplat
  • Cisplatina
  • Cisplatinum
  • Cisplatyl
  • Citoplatino
  • Citosin
  • Cysplatyna
  • DDP
  • Lederplatin
  • Metaplatin
  • Neoplatin
  • Peyrone's Chloride
  • Peyrone's Salt
  • Placis
  • Plastistil
  • Platamine
  • Platiblastin
  • Platiblastin-S
  • Platinex
  • Platinol
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Platinum
  • Platinum Diamminodichloride
  • Platiran
  • Platistin
  • Platosin
Drug: Etoposide
Given IV
Other Names:
  • Demethyl Epipodophyllotoxin Ethylidine Glucoside
  • EPEG
  • Lastet
  • Toposar
  • Vepesid
  • VP 16-213
  • VP-16
  • VP-16-213
Other: Laboratory Biomarker Analysis
Correlative studies
Biological: Nivolumab
Given IV
Other Names:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
Experimental: Arm B (CE)
Patients receive carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Drug: Carboplatin
Given IV
Other Names:
  • Blastocarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Carbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatinum
  • Paraplatin
  • Paraplatin AQ
  • Paraplatine
  • Platinwas
  • Ribocarbo
Drug: Cisplatin
Given IV
Other Names:
  • Abiplatin
  • Blastolem
  • Briplatin
  • CDDP
  • Cis-diammine-dichloroplatinum
  • Cis-diamminedichloridoplatinum
  • Cis-diamminedichloro Platinum (II)
  • Cis-diamminedichloroplatinum
  • Cis-dichloroammine Platinum (II)
  • Cis-platinous Diamine Dichloride
  • Cis-platinum
  • Cis-platinum II
  • Cis-platinum II Diamine Dichloride
  • Cismaplat
  • Cisplatina
  • Cisplatinum
  • Cisplatyl
  • Citoplatino
  • Citosin
  • Cysplatyna
  • DDP
  • Lederplatin
  • Metaplatin
  • Neoplatin
  • Peyrone's Chloride
  • Peyrone's Salt
  • Placis
  • Plastistil
  • Platamine
  • Platiblastin
  • Platiblastin-S
  • Platinex
  • Platinol
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Platinum
  • Platinum Diamminodichloride
  • Platiran
  • Platistin
  • Platosin
Drug: Etoposide
Given IV
Other Names:
  • Demethyl Epipodophyllotoxin Ethylidine Glucoside
  • EPEG
  • Lastet
  • Toposar
  • Vepesid
  • VP 16-213
  • VP-16
  • VP-16-213
Other: Laboratory Biomarker Analysis
Correlative studies



Primary Outcome Measures :
  1. Progression free survival [ Time Frame: From randomization to documented disease progression or death from any cause, whichever occurs first, assessed up to 5 years ]
    Will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. Will use a logrank test stratified on the randomization stratification factors with a one-sided type I error rate of 10%.


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: From randomization to death from any cause, and patients who are thought to be alive at the time of final analysis will be censored at the last date of contact, assessed up to 5 years ]
    Will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. Will use a logrank test stratified on the randomization stratification factors with a one-sided type I error rate of 10%.

  2. Best overall response rate [ Time Frame: Up to 5 years ]
    Will be assessed by Response Evaluation Criteria in Solid Tumors 1.1. Will be compared using Fisher's exact tests with a one-sided type I error rate of 10%; multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes. Continuous outcomes will be analyzed using Wilcoxon rank sum test, and multivariable linear regression models may be used to adjust for multiple associations with outcome.

  3. Incidence of toxicities [ Time Frame: Up to 5 years ]
    Will be assessed by Common Terminology Criteria for Adverse Events version 4.0 criteria. Will be compared using Fisher's exact tests with a one-sided type I error rate of 10%; multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes. Continuous outcomes will be analyzed using Wilcoxon rank sum test, and multivariable linear regression models may be used to adjust for multiple associations with outcome.


Other Outcome Measures:
  1. Immune biomarkers and biomarkers correlatives [ Time Frame: Up to 5 years ]
    Will be analyzed for association with subject demographics and/or disease characteristics using the Kruskal Wallis test.

  2. Serial circulating tumor DNA [ Time Frame: Up to 5 years ]
    Will be analyzed for association with subject demographics and/or disease characteristics using the Kruskal Wallis test.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed extensive stage small cell lung cancer and must be a candidate for systemic therapy; NOTE: The extensive disease SCLC classification for this protocol includes all patients with disease sites not defined as limited stage; limited stage disease category includes patients with disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and/or ipsilateral supraclavicular nodes; extensive disease patients are defined as those patients with extrathoracic metastatic disease, malignant pleural effusion, bilateral or contralateral supraclavicular adenopathy
  • Patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Absolute neutrophil count >= 1,500/mm^3 must be obtained =< 7 days prior to protocol registration
  • Platelets >= 100,000/mm^3 must be obtained =< 7 days prior to protocol registration
  • Leukocytes >= 3000/mm^3 must be obtained =< 7 days prior to protocol registration
  • Hemoglobin >= 9 g/dL must be obtained =< 7 days prior to protocol registration
  • Total bilirubin =< 1.5 X institutional upper limit of normal (ULN) (except subjects with Gilbert syndrome, who can have total bilirubin < 3 mg/dL) must be obtained =< 7 days prior to protocol registration
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 X institutional upper limit of normal (ULN) (=< 5 X if liver function test [LFT] elevations due to known liver metastases) must be obtained =< 7 days prior to protocol registration
  • Serum creatinine =< 1.5 x ULN or calculated creatinine clearance > 50 mL/min (using the Cockcroft-Gault formula) must be obtained =< 7 days prior to protocol registration
  • Patients are eligible if central nervous system (CNS) metastases are adequately treated and neurological symptoms have returned to baseline or are controlled for at least 2 weeks prior to enrollment; in addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of =< 10 mg daily prednisone (or equivalent); patients with untreated CNS metastases are eligible if they are not symptomatic and the lesions are less than 1 cm in size
  • Patients cannot have had prior chemotherapy or biologic therapy for small cell lung cancer for front line treatment; patients receiving prior whole brain radiation cannot register within 7 days after completion of radiation, and must have resolved adverse events attributed to radiation to =< grade 1
  • Patients who have received prior chemoradiation for limited-stage SCLC must have been treated with curative intent at least 6 months since last treatment from diagnosis of extensive-stage SCLC
  • Patients may not be receiving any other investigational agents while on study
  • Patients must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab or other agents used in the study
  • Women must not be pregnant or breast-feeding; breastfeeding must be discontinued or the subject is not eligible for the study; all females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e. has had menses at any time in the preceding 24 consecutive months)
  • Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must use an accepted and effective method of contraception or abstain from sexual intercourse for at least one week prior to the start of treatment, and continue for 5 months after the last dose of protocol treatment for women of childbearing potential and 7 months after the last dose of protocol treatment for males who are sexually active with WOCBP
  • No prior or current invasive malignancy (except non-melanomatous skin cancer, localized bladder and prostate cancer) unless disease free for a minimum of 2 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible);
  • No prior systemic treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways;
  • Patient must not have leptomeningeal disease
  • No patients with an active, known or suspected autoimmune disease and neuromuscular paraneoplastic syndromes including but not limited to myasthenia gravis, Lambert-Eaton myasthenic syndrome, limbic encephalitis, myositis, Guillain-Barre; subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
  • No patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 7 days of randomization; inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
  • No patients with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
  • Patients must NOT have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
  • Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection, patients are excluded
  • Patients are ineligible if administration of a live, attenuated vaccine within 4 weeks before randomization
  • No history of severe hypersensitivity reaction to any monoclonal antibody or allergy to study drug components;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03382561


  Hide Study Locations
Locations
United States, California
PCR Oncology Recruiting
Arroyo Grande, California, United States, 93420
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
United States, Idaho
Saint Alphonsus Cancer Care Center-Boise Recruiting
Boise, Idaho, United States, 83706
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint Alphonsus Cancer Care Center-Caldwell Recruiting
Caldwell, Idaho, United States, 83605
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Kootenai Medical Center Recruiting
Coeur d'Alene, Idaho, United States, 83814
Contact: Benjamin T. Marchello    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: Benjamin T. Marchello         
Walter Knox Memorial Hospital Recruiting
Emmett, Idaho, United States, 83617
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Idaho Urologic Institute-Meridian Recruiting
Meridian, Idaho, United States, 83642
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint Alphonsus Medical Center-Nampa Recruiting
Nampa, Idaho, United States, 83686
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Kootenai Cancer Center Recruiting
Post Falls, Idaho, United States, 83854
Contact: Benjamin T. Marchello    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: Benjamin T. Marchello         
Kootenai Cancer Clinic Recruiting
Sandpoint, Idaho, United States, 83864
Contact: Benjamin T. Marchello    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: Benjamin T. Marchello         
United States, Illinois
John H Stroger Jr Hospital of Cook County Recruiting
Chicago, Illinois, United States, 60612
Contact: Thomas E. Lad    312-864-5204      
Principal Investigator: Thomas E. Lad         
United States, Iowa
Iowa Methodist Medical Center Recruiting
Des Moines, Iowa, United States, 50309
Contact: Robert J. Behrens    515-241-6727      
Principal Investigator: Robert J. Behrens         
Medical Oncology and Hematology Associates-Des Moines Recruiting
Des Moines, Iowa, United States, 50309
Contact: Robert J. Behrens    515-282-2921      
Principal Investigator: Robert J. Behrens         
Broadlawns Medical Center Recruiting
Des Moines, Iowa, United States, 50314
Contact: Robert J. Behrens    515-282-2200      
Principal Investigator: Robert J. Behrens         
Iowa Lutheran Hospital Recruiting
Des Moines, Iowa, United States, 50316
Contact: Robert J. Behrens    515-241-8704      
Principal Investigator: Robert J. Behrens         
Methodist West Hospital Recruiting
West Des Moines, Iowa, United States, 50266-7700
Contact: Robert J. Behrens    515-343-1000      
Principal Investigator: Robert J. Behrens         
United States, Louisiana
Ochsner Health Center-Summa Recruiting
Baton Rouge, Louisiana, United States, 70809
Contact: Suma P. Satti    225-761-5346    Camille.Beck@Ochsner.org   
Principal Investigator: Suma P. Satti         
Medical Center of Baton Rouge Recruiting
Baton Rouge, Louisiana, United States, 70816
Contact: Suma P. Satti    225-761-5346    Camille.Beck@Ochsner.org   
Principal Investigator: Suma P. Satti         
Ochsner Medical Center Jefferson Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Suma P. Satti    504-703-8712    Gregory.Johnstone@ochsner.org   
Principal Investigator: Suma P. Satti         
United States, Maryland
Frederick Memorial Hospital Recruiting
Frederick, Maryland, United States, 21701
Contact: Elhamy D. Eskander    240-566-3584    clinicaltrials@fmh.org   
Principal Investigator: Elhamy D. Eskander         
United States, Michigan
Saint Joseph Mercy Hospital Recruiting
Ann Arbor, Michigan, United States, 48106
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
IHA Hematology Oncology Consultants-Brighton Recruiting
Brighton, Michigan, United States, 48114
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint Joseph Mercy Brighton Recruiting
Brighton, Michigan, United States, 48114
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
IHA Hematology Oncology Consultants-Canton Recruiting
Canton, Michigan, United States, 48188
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint Joseph Mercy Canton Recruiting
Canton, Michigan, United States, 48188
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Caro Cancer Center Recruiting
Caro, Michigan, United States, 48723
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
IHA Hematology Oncology Consultants-Chelsea Recruiting
Chelsea, Michigan, United States, 48118
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint Joseph Mercy Chelsea Recruiting
Chelsea, Michigan, United States, 48118
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Hematology Oncology Consultants-Clarkston Recruiting
Clarkston, Michigan, United States, 48346
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Newland Medical Associates-Clarkston Recruiting
Clarkston, Michigan, United States, 48346
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint John Hospital and Medical Center Recruiting
Detroit, Michigan, United States, 48236
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Great Lakes Cancer Management Specialists-Doctors Park Recruiting
East China Township, Michigan, United States, 48054
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Green Bay Oncology - Escanaba Recruiting
Escanaba, Michigan, United States, 49829
Contact: Brian L. Burnette    920-433-8889    Christy.Gilchrist@hshs.org   
Principal Investigator: Brian L. Burnette         
Genesee Cancer and Blood Disease Treatment Center Recruiting
Flint, Michigan, United States, 48503
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Genesee Hematology Oncology PC Recruiting
Flint, Michigan, United States, 48503
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Genesys Hurley Cancer Institute Recruiting
Flint, Michigan, United States, 48503
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Hurley Medical Center Recruiting
Flint, Michigan, United States, 48503
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center Recruiting
Grosse Pointe Woods, Michigan, United States, 48236
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Lymphoma Clinic of Michigan Recruiting
Grosse Pointe Woods, Michigan, United States, 48236
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Michigan Breast Specialists-Grosse Pointe Woods Recruiting
Grosse Pointe Woods, Michigan, United States, 48236
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Sparrow Hospital Recruiting
Lansing, Michigan, United States, 48912
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Hope Cancer Clinic Recruiting
Livonia, Michigan, United States, 48154
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint Mary Mercy Hospital Recruiting
Livonia, Michigan, United States, 48154
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Great Lakes Cancer Management Specialists-Macomb Medical Campus Recruiting
Macomb, Michigan, United States, 48044
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Michigan Breast Specialists-Macomb Township Recruiting
Macomb, Michigan, United States, 48044
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint Mary's Oncology/Hematology Associates of Marlette Recruiting
Marlette, Michigan, United States, 48453
Contact: Philip J. Stella    989-343-2487      
Principal Investigator: Philip J. Stella         
21st Century Oncology-Pontiac Recruiting
Pontiac, Michigan, United States, 48341
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Hope Cancer Center Recruiting
Pontiac, Michigan, United States, 48341
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Newland Medical Associates-Pontiac Recruiting
Pontiac, Michigan, United States, 48341
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint Joseph Mercy Oakland Recruiting
Pontiac, Michigan, United States, 48341
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Huron Medical Center PC Recruiting
Port Huron, Michigan, United States, 48060
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Lake Huron Medical Center Recruiting
Port Huron, Michigan, United States, 48060
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Great Lakes Cancer Management Specialists-Rochester Hills Recruiting
Rochester Hills, Michigan, United States, 48309
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint Mary's of Michigan Recruiting
Saginaw, Michigan, United States, 48601
Contact: Philip J. Stella       ecog.rss@jimmy.harvard.edu   
Principal Investigator: Philip J. Stella         
Oncology Hematology Associates of Saginaw Valley PC Recruiting
Saginaw, Michigan, United States, 48604
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Bhadresh Nayak MD PC-Sterling Heights Recruiting
Sterling Heights, Michigan, United States, 48312
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint Joseph Health System-Tawas City Recruiting
Tawas City, Michigan, United States, 48764
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Advanced Breast Care Center PLLC Recruiting
Warren, Michigan, United States, 48088
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Great Lakes Cancer Management Specialists-Macomb Professional Building Recruiting
Warren, Michigan, United States, 48093
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Macomb Hematology Oncology PC Recruiting
Warren, Michigan, United States, 48093
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Michigan Breast Specialists-Warren Recruiting
Warren, Michigan, United States, 48093
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint John Macomb-Oakland Hospital Recruiting
Warren, Michigan, United States, 48093
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint Mary's Oncology/Hematology Associates of West Branch Recruiting
West Branch, Michigan, United States, 48661
Contact: Philip J. Stella    989-343-2487      
Principal Investigator: Philip J. Stella         
Huron Gastroenterology PC Recruiting
Ypsilanti, Michigan, United States, 48106
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
IHA Hematology Oncology Consultants-Ann Arbor Recruiting
Ypsilanti, Michigan, United States, 48197
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
United States, Minnesota
Sanford Clinic North-Bemidgi Recruiting
Bemidji, Minnesota, United States, 56601
Contact: Preston D. Steen    218-333-5000      
Principal Investigator: Preston D. Steen         
United States, Montana
Community Hospital of Anaconda Recruiting
Anaconda, Montana, United States, 59711
Contact: Benjamin T. Marchello    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: Benjamin T. Marchello         
Billings Clinic Cancer Center Recruiting
Billings, Montana, United States, 59101
Contact: Benjamin T. Marchello    800-996-2663    research@billingsclinic.org   
Principal Investigator: Benjamin T. Marchello         
Bozeman Deaconess Hospital Recruiting
Bozeman, Montana, United States, 59715
Contact: Benjamin T. Marchello    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: Benjamin T. Marchello         
Benefis Healthcare- Sletten Cancer Institute Recruiting
Great Falls, Montana, United States, 59405
Contact: Benjamin T. Marchello    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: Benjamin T. Marchello         
Great Falls Clinic Recruiting
Great Falls, Montana, United States, 59405
Contact: Benjamin T. Marchello    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: Benjamin T. Marchello         
Saint Peter's Community Hospital Recruiting
Helena, Montana, United States, 59601
Contact: Benjamin T. Marchello       ecog.rss@jimmy.harvard.edu   
Principal Investigator: Benjamin T. Marchello         
Kalispell Regional Medical Center Recruiting
Kalispell, Montana, United States, 59901
Contact: Benjamin T. Marchello    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: Benjamin T. Marchello         
Community Medical Hospital Recruiting
Missoula, Montana, United States, 59804
Contact: Benjamin T. Marchello    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: Benjamin T. Marchello         
United States, Nebraska
Nebraska Hematology and Oncology Recruiting
Lincoln, Nebraska, United States, 68506
Contact: Gamini S. Soori    402-484-4911      
Principal Investigator: Gamini S. Soori         
Nebraska Cancer Research Center Recruiting
Lincoln, Nebraska, United States, 68510
Contact: Gamini S. Soori    800-487-8786      
Principal Investigator: Gamini S. Soori         
Southeast Nebraska Cancer Center Recruiting
Lincoln, Nebraska, United States, 68510
Contact: Gamini S. Soori    402-327-7363      
Principal Investigator: Gamini S. Soori         
Faith Regional Health Services Carson Cancer Center Recruiting
Norfolk, Nebraska, United States, 68701
Contact: Gamini S. Soori    402-991-0070    mwilwerding@canceralliance-ne.org   
Principal Investigator: Gamini S. Soori         
Great Plains Health Callahan Cancer Center Recruiting
North Platte, Nebraska, United States, 69101
Contact: Gamini S. Soori    402-991-0070    mwilwerding@canceralliance-ne.org   
Principal Investigator: Gamini S. Soori         
Nebraska Methodist Hospital Recruiting
Omaha, Nebraska, United States, 68114
Contact: Robert M. Langdon    402-354-5144      
Principal Investigator: Robert M. Langdon         
Nebraska Cancer Specialists - Omaha Recruiting
Omaha, Nebraska, United States, 68124
Contact: Gamini S. Soori    402-991-0070    mwilwerding@canceralliance-ne.org   
Principal Investigator: Gamini S. Soori         
Oncology Hematology West PC Recruiting
Omaha, Nebraska, United States, 68130
Contact: Gamini S. Soori    402-334-4773      
Principal Investigator: Gamini S. Soori         
Regional West Medical Center Cancer Center Recruiting
Scottsbluff, Nebraska, United States, 69361
Contact: Gamini S. Soori    402-991-0070    mwilwerding@canceralliance-ne.org   
Principal Investigator: Gamini S. Soori         
United States, Nevada
Carson Tahoe Regional Medical Center Recruiting
Carson City, Nevada, United States, 89703
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Cancer and Blood Specialists-Henderson Recruiting
Henderson, Nevada, United States, 89052
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada - Henderson Recruiting
Henderson, Nevada, United States, 89052
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada-Horizon Ridge Recruiting
Henderson, Nevada, United States, 89052
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Las Vegas Cancer Center-Henderson Recruiting
Henderson, Nevada, United States, 89052
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Nevada Cancer Specialists-Saint Rose Recruiting
Henderson, Nevada, United States, 89052
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
21st Century Oncology-Henderson Recruiting
Henderson, Nevada, United States, 89074
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada-Southeast Henderson Recruiting
Henderson, Nevada, United States, 89074
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Desert West Surgery Recruiting
Las Vegas, Nevada, United States, 89102
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Nevada Cancer Specialists?Oakey Recruiting
Las Vegas, Nevada, United States, 89102
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
University Medical Center of Southern Nevada Recruiting
Las Vegas, Nevada, United States, 89102
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Hope Cancer Care of Nevada Recruiting
Las Vegas, Nevada, United States, 89103
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Cancer and Blood Specialists-Shadow Recruiting
Las Vegas, Nevada, United States, 89106
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Radiation Oncology Centers of Nevada Central Recruiting
Las Vegas, Nevada, United States, 89106
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
21st Century Oncology Recruiting
Las Vegas, Nevada, United States, 89109
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway Recruiting
Las Vegas, Nevada, United States, 89109
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
HealthCare Partners Medical Group Oncology/Hematology-San Martin Recruiting
Las Vegas, Nevada, United States, 89113
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Radiation Oncology Centers of Nevada Southeast Recruiting
Las Vegas, Nevada, United States, 89119
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Cancer Therapy and Integrative Medicine Recruiting
Las Vegas, Nevada, United States, 89121
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
21st Century Oncology-Vegas Tenaya Recruiting
Las Vegas, Nevada, United States, 89128
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Ann M Wierman MD LTD Recruiting
Las Vegas, Nevada, United States, 89128
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Cancer and Blood Specialists-Tenaya Recruiting
Las Vegas, Nevada, United States, 89128
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada - Northwest Recruiting
Las Vegas, Nevada, United States, 89128
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
HealthCare Partners Medical Group Oncology/Hematology-Tenaya Recruiting
Las Vegas, Nevada, United States, 89128
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Nevada Cancer Specialists-Tenaya Recruiting
Las Vegas, Nevada, United States, 89128
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada-Summerlin Recruiting
Las Vegas, Nevada, United States, 89144
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Summerlin Hospital Medical Center Recruiting
Las Vegas, Nevada, United States, 89144
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Las Vegas Cancer Center-Medical Center Recruiting
Las Vegas, Nevada, United States, 89148-2405
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
21st Century Oncology-Fort Apache Recruiting
Las Vegas, Nevada, United States, 89148
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada Recruiting
Las Vegas, Nevada, United States, 89148
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Nevada Cancer Specialists-Fort Apache Recruiting
Las Vegas, Nevada, United States, 89148
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills Recruiting
Las Vegas, Nevada, United States, 89149
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Comprehensive Cancer Centers of Nevada - Central Valley Recruiting
Las Vegas, Nevada, United States, 89169
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
University Cancer Center Recruiting
Las Vegas, Nevada, United States, 89169
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Hope Cancer Care of Nevada-Pahrump Recruiting
Pahrump, Nevada, United States, 89048
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Renown Regional Medical Center Recruiting
Reno, Nevada, United States, 89502
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
Saint Mary's Regional Medical Center Recruiting
Reno, Nevada, United States, 89503
Contact: John A. Ellerton       ecog.rss@jimmy.harvard.edu   
Principal Investigator: John A. Ellerton         
Radiation Oncology Associates Recruiting
Reno, Nevada, United States, 89509
Contact: John A. Ellerton    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
United States, New Jersey
Inspira Medical Center Woodbury Recruiting
Woodbury, New Jersey, United States, 08096
Contact: Carl J. Minniti       ecog.rss@jimmy.harvard.edu   
Principal Investigator: Carl J. Minniti         
United States, New York
Arnot Ogden Medical Center/Falck Cancer Center Recruiting
Elmira, New York, United States, 14905
Contact: Serge Dauphin    607-271-7000      
Principal Investigator: Serge Dauphin         
United States, North Dakota
Sanford Bismarck Medical Center Recruiting
Bismarck, North Dakota, United States, 58501
Contact: Preston D. Steen    701-323-5760    tamara.fischer@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
Roger Maris Cancer Center Recruiting
Fargo, North Dakota, United States, 58122
Contact: Preston D. Steen    701-234-6161      
Principal Investigator: Preston D. Steen         
Sanford Broadway Medical Center Recruiting
Fargo, North Dakota, United States, 58122
Contact: Preston D. Steen    800-437-4010      
Principal Investigator: Preston D. Steen         
Trinity Cancer Care Center Recruiting
Minot, North Dakota, United States, 58701
Contact: Patanit Watanaboonyakhet    800-862-0005      
Principal Investigator: Patanit Watanaboonyakhet         
United States, Ohio
Strecker Cancer Center-Belpre Recruiting
Belpre, Ohio, United States, 45714
Contact: Timothy D. Moore    800-523-3977    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Adena Regional Medical Center Recruiting
Chillicothe, Ohio, United States, 45601
Contact: Timothy D. Moore    877-779-7585    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
MetroHealth Medical Center Recruiting
Cleveland, Ohio, United States, 44109
Contact: Bruce J. Averbook    216-778-8526    dstrater@metrohealth.org   
Principal Investigator: Bruce J. Averbook         
Mount Carmel East Hospital Recruiting
Columbus, Ohio, United States, 43213
Contact: Timothy D. Moore    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Columbus Oncology and Hematology Associates Inc Recruiting
Columbus, Ohio, United States, 43214
Contact: Timothy D. Moore    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Riverside Methodist Hospital Recruiting
Columbus, Ohio, United States, 43214
Contact: Timothy D. Moore    614-566-4475    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Grant Medical Center Recruiting
Columbus, Ohio, United States, 43215
Contact: Timothy D. Moore    614-566-4475    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
The Mark H Zangmeister Center Recruiting
Columbus, Ohio, United States, 43219
Contact: Timothy D. Moore    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Mount Carmel Health Center West Recruiting
Columbus, Ohio, United States, 43222
Contact: Timothy D. Moore    614-234-5433    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Doctors Hospital Recruiting
Columbus, Ohio, United States, 43228
Contact: Timothy D. Moore    614-566-3275    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Delaware Health Center-Grady Cancer Center Recruiting
Delaware, Ohio, United States, 43015
Contact: Timothy D. Moore    740-615-0227    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Delaware Radiation Oncology Recruiting
Delaware, Ohio, United States, 43015
Contact: Timothy D. Moore       ecog.rss@jimmy.harvard.edu   
Principal Investigator: Timothy D. Moore         
Grady Memorial Hospital Recruiting
Delaware, Ohio, United States, 43015
Contact: Timothy D. Moore    740-615-2403    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Fairfield Medical Center Recruiting
Lancaster, Ohio, United States, 43130
Contact: Timothy D. Moore    740-687-8863    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
OhioHealth Mansfield Hospital Recruiting
Mansfield, Ohio, United States, 44903
Contact: Timothy D. Moore    419-526-8018    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Marietta Memorial Hospital Recruiting
Marietta, Ohio, United States, 45750
Contact: Timothy D. Moore    800-523-3977    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
OhioHealth Marion General Hospital Recruiting
Marion, Ohio, United States, 43302
Contact: Timothy D. Moore    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Knox Community Hospital Recruiting
Mount Vernon, Ohio, United States, 43050
Contact: Timothy D. Moore    740-393-9000    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Licking Memorial Hospital Recruiting
Newark, Ohio, United States, 43055
Contact: Timothy D. Moore    740-348-4000    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Newark Radiation Oncology Recruiting
Newark, Ohio, United States, 43055
Contact: Timothy D. Moore    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Southern Ohio Medical Center Recruiting
Portsmouth, Ohio, United States, 45662
Contact: Timothy D. Moore    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Saint Ann's Hospital Recruiting
Westerville, Ohio, United States, 43081
Contact: Timothy D. Moore       ecog.rss@jimmy.harvard.edu   
Principal Investigator: Timothy D. Moore         
Genesis Healthcare System Cancer Care Center Recruiting
Zanesville, Ohio, United States, 43701
Contact: Timothy D. Moore    740-454-5232    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
United States, Oregon
Saint Alphonsus Medical Center-Baker City Recruiting
Baker City, Oregon, United States, 97814
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Saint Alphonsus Medical Center-Ontario Recruiting
Ontario, Oregon, United States, 97914
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
United States, Pennsylvania
Lehigh Valley Hospital-Cedar Crest Recruiting
Allentown, Pennsylvania, United States, 18103
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Lehigh Valley Hospital - Muhlenberg Recruiting
Bethlehem, Pennsylvania, United States, 18017
Contact: Philip J. Stella    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: Philip J. Stella         
Pocono Medical Center Recruiting
East Stroudsburg, Pennsylvania, United States, 18301
Contact: Philip J. Stella    570-422-1700    ann.foster@lvhn.org   
Principal Investigator: Philip J. Stella         
Ephrata Cancer Center Recruiting
Ephrata, Pennsylvania, United States, 17522
Contact: Amir Tabatabai    717-721-4840      
Principal Investigator: Amir Tabatabai         
Ephrata Community Hospital Recruiting
Ephrata, Pennsylvania, United States, 17522
Contact: Amir Tabatabai    888-823-5923    ctsucontact@westat.com   
Principal Investigator: Amir Tabatabai         
Adams Cancer Center Recruiting
Gettysburg, Pennsylvania, United States, 17325
Contact: Amir Tabatabai    877-441-7957      
Principal Investigator: Amir Tabatabai         
Cherry Tree Cancer Center Recruiting
Hanover, Pennsylvania, United States, 17331
Contact: Amir Tabatabai    877-441-7957      
Principal Investigator: Amir Tabatabai         
Lehigh Valley Hospital-Hazleton Recruiting
Hazleton, Pennsylvania, United States, 18201
Contact: Philip J. Stella       ecog.rss@jimmy.harvard.edu   
Principal Investigator: Philip J. Stella         
Sechler Family Cancer Center Recruiting
Lebanon, Pennsylvania, United States, 17042
Contact: Amir Tabatabai    717-741-8303    doxenberg@wellspan.org   
Principal Investigator: Amir Tabatabai         
ECOG-ACRIN Cancer Research Group Recruiting
Philadelphia, Pennsylvania, United States, 19103
Contact: Ticiana A. Leal    608-263-9063    tbleal@medicine.wisc.edu   
Principal Investigator: Ticiana A. Leal         
Pottstown Hospital Recruiting
Pottstown, Pennsylvania, United States, 19464
Contact: Wei Song    610-327-7544      
Principal Investigator: Wei Song         
Guthrie Medical Group PC-Robert Packer Hospital Recruiting
Sayre, Pennsylvania, United States, 18840
Contact: Philip A. Lowry    800-836-0388      
Principal Investigator: Philip A. Lowry         
WellSpan Health-York Cancer Center Recruiting
York, Pennsylvania, United States, 17403
Contact: Amir Tabatabai    877-441-7957      
Principal Investigator: Amir Tabatabai         
WellSpan Health-York Hospital Recruiting
York, Pennsylvania, United States, 17403
Contact: Amir Tabatabai    877-441-7957      
Principal Investigator: Amir Tabatabai         
United States, South Dakota
Sanford Cancer Center Oncology Clinic Recruiting
Sioux Falls, South Dakota, United States, 57104
Contact: Preston D. Steen    605-312-3320      
Principal Investigator: Preston D. Steen         
Sanford USD Medical Center - Sioux Falls Recruiting
Sioux Falls, South Dakota, United States, 57117-5134
Contact: Preston D. Steen    605-312-3320    OncologyClinicalTrialsSF@SanfordHealth.org   
Principal Investigator: Preston D. Steen         
United States, Tennessee
Wellmont Bristol Regional Medical Center Recruiting
Bristol, Tennessee, United States, 37620
Contact: Asheesh Shipstone    423-578-8538    justin.reynolds@wellmont.org   
Principal Investigator: Asheesh Shipstone         
Wellmont Medical Associates Oncology and Hematology-Johnson City Recruiting
Johnson City, Tennessee, United States, 37604
Contact: Asheesh Shipstone    423-578-8538    justin.reynolds@wellmont.org   
Principal Investigator: Asheesh Shipstone         
Wellmont Holston Valley Hospital and Medical Center Recruiting
Kingsport, Tennessee, United States, 37660
Contact: Asheesh Shipstone    423-578-8538    justin.reynolds@wellmont.org   
Principal Investigator: Asheesh Shipstone         
Wellmont Medical Associates Oncology and Hematology-Kingsport Recruiting
Kingsport, Tennessee, United States, 37660
Contact: Asheesh Shipstone    423-578-8538    justin.reynolds@wellmont.org   
Principal Investigator: Asheesh Shipstone         
United States, Virginia
Wellmont Medical Associates-Bristol Recruiting
Bristol, Virginia, United States, 24201
Contact: Asheesh Shipstone    423-578-8538    justin.reynolds@wellmont.org   
Principal Investigator: Asheesh Shipstone         
Southwest VA Regional Cancer Center Recruiting
Norton, Virginia, United States, 24273
Contact: Asheesh Shipstone    423-578-8538    justin.reynolds@wellmont.org   
Principal Investigator: Asheesh Shipstone         
United States, Wisconsin
Saint Vincent Hospital Cancer Center Green Bay Recruiting
Green Bay, Wisconsin, United States, 54301
Contact: Brian L. Burnette    920-433-8889    Christy.Gilchrist@hshs.org   
Principal Investigator: Brian L. Burnette         
Saint Vincent Hospital Cancer Center at Saint Mary's Recruiting
Green Bay, Wisconsin, United States, 54303
Contact: Brian L. Burnette       ecog.rss@jimmy.harvard.edu   
Principal Investigator: Brian L. Burnette         
Holy Family Memorial Hospital Recruiting
Manitowoc, Wisconsin, United States, 54221
Contact: Brian L. Burnette    920-320-2749      
Principal Investigator: Brian L. Burnette         
Saint Vincent Hospital Cancer Center at Marinette Recruiting
Marinette, Wisconsin, United States, 54143
Contact: Brian L. Burnette    920-433-8889    Christy.Gilchrist@hshs.org   
Principal Investigator: Brian L. Burnette         
Green Bay Oncology - Oconto Falls Recruiting
Oconto Falls, Wisconsin, United States, 54154
Contact: Brian L. Burnette    920-433-8889    Christy.Gilchrist@hshs.org   
Principal Investigator: Brian L. Burnette         
HSHS Saint Nicholas Hospital Recruiting
Sheboygan, Wisconsin, United States, 53081
Contact: Brian L. Burnette    920-433-8889    Christy.Gilchrist@hshs.org   
Principal Investigator: Brian L. Burnette         
Saint Vincent Hospital Cancer Center at Sturgeon Bay Recruiting
Sturgeon Bay, Wisconsin, United States, 54235-1495
Contact: Brian L. Burnette    920-433-8889    Christy.Gilchrist@hshs.org   
Principal Investigator: Brian L. Burnette         
United States, Wyoming
Billings Clinic-Cody Recruiting
Cody, Wyoming, United States, 82414
Contact: Benjamin T. Marchello    800-996-2663    research@billingsclinic.org   
Principal Investigator: Benjamin T. Marchello         
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Principal Investigator: Ticiana Leal ECOG-ACRIN Cancer Research Group

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03382561     History of Changes
Other Study ID Numbers: NCI-2017-02367
NCI-2017-02367 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
EA5161 ( Other Identifier: ECOG-ACRIN Cancer Research Group )
EA5161 ( Other Identifier: CTEP )
U10CA180820 ( U.S. NIH Grant/Contract )
First Posted: December 26, 2017    Key Record Dates
Last Update Posted: May 23, 2018
Last Verified: May 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Lung Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Nivolumab
Etoposide phosphate
Cisplatin
Carboplatin
Etoposide
Podophyllotoxin
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Keratolytic Agents
Dermatologic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators